CD44 and COVID-19: The stratification according to disease severity showed few statistically significant differences in SARS-CoV-2-stimulated gene expression between the severe COVID-19 (ERAP1 and IFI16, ANOVA Tukey post hoc test, p adjusted <0.05) and pauci COVID-19 patients (ERAP1, CD44, ANOVA Tukey post hoc test, p adjusted <0.05) compared to thew controls (Supplementary Figure S9).